Xeris Biopharma Holdings, Inc. (XERS) |
|
1.855 0.015 (0.82%)
|
09-26 14:21 |
|
Open: |
1.81 |
Pre. Close: |
1.84 |
|
High:
|
1.9201 |
Low:
|
1.81 |
|
Volume:
|
537,761 |
Market Cap:
|
256(M) |
|
|
|
Technical analysis |
as of: 2023-09-26 1:52:45 PM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 2.55 One year: 2.88 |
| Support: |
Support1: 1.73 Support2: 1.44 |
| Resistance: |
Resistance1: 2.18 Resistance2: 2.47 |
| Pivot: |
1.99  |
| Moving Average: |
MA(5): 1.84 MA(20): 2.06
MA(100): 2.49 MA(250): 1.87 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 14 %D(3): 8.7 |
| RSI: |
RSI(14): 31.1 |
| 52-week: |
High: 3.06 Low: 0.97 |
| Average Vol(K): |
3-Month: 947 (K) 10-Days: 1,007 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ XERS ] has closed above bottom band by 17.7%. Bollinger Bands are 13.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.84 - 1.86 |
1.86 - 1.87 |
|
Low:
|
1.7 - 1.72 |
1.72 - 1.73 |
|
Close:
|
1.82 - 1.84 |
1.84 - 1.86 |
|
Company Description |
|
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. |
Headline News |
Mon, 25 Sep 2023
As the Market Struggles to Bounce, I'm Watching These 7 Stocks - RealMoney
Thu, 14 Sep 2023
Xeris to Participate in the 2023 Cantor Global Healthcare Conference - Business Wire
Wed, 13 Sep 2023
Where Does Xeris Biopharma Holdings Inc (XERS) Stock Fall in the Biotechnology Field After It Has Fallen -4.59% This Week? - InvestorsObserver
Mon, 28 Aug 2023
Xeris to Participate at the H.C. Wainwright 25th Annual Global ... - Business Wire
Mon, 28 Aug 2023
Craig-Hallum Initiates Coverage of Xeris Biopharma Holdings ... - Nasdaq
Tue, 01 Aug 2023
Xeris Biopharma to Report Second Quarter 2023 Financial Results ... - Business Wire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
138 (M) |
| Shares Float |
134 (M) |
|
% Held by Insiders
|
1.8 (%) |
|
% Held by Institutions
|
38.2 (%) |
|
Shares Short
|
7,420 (K) |
|
Shares Short P.Month
|
8,300 (K) |
Stock Financials |
|
EPS
|
-0.5 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.1 |
|
Profit Margin (%)
|
-53.3 |
|
Operating Margin (%)
|
-40.8 |
|
Return on Assets (ttm)
|
-10.6 |
|
Return on Equity (ttm)
|
-163.2 |
|
Qtrly Rev. Growth
|
50.2 |
|
Gross Profit (p.s.)
|
0.63 |
|
Sales Per Share
|
0.97 |
|
EBITDA (p.s.)
|
-0.31 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-74 (M) |
|
Levered Free Cash Flow
|
-35 (M) |
Stock Valuations |
|
PE Ratio
|
-3.69 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
18.39 |
|
Price to Sales
|
1.89 |
|
Price to Cash Flow
|
-3.45 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
